AbbVie Inc. · NYSE:ABBV
AbbVie — Fact Sheet (January 2015)
6 slides from AbbVie's fact sheet, January 2015
Slide 1: Hepatitis C Clinical Trials Program Overview
abbvie Hepatitis C Clinical Trials Program Overview VIEKIRA PAK™, (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) with or without ribavirin (RBV), is indicated for the treatment of adult patients with genotype 1 chronic hepatitis C virus infection, including those with compensate
Slide 2: PEARL and TURQUOISE-II studies outcomes
abbvie The PEARL-II, PEARL-III, and PEARL-IV studies sought to determine if adults without cirrhosis could be treated with VIEKIRA PAK without the use of RBV. Patients in PEARL-III and PEARL-IV were new to therapy, and patients in PEARL-II had failed previous treatment with pegIFN and RBV. Outcome f
Slide 3: TURQUOISE-I and CORAL-I studies in special populations
abbvie VIEKIRA PAK + RBV was studied in certain additional patient populations, including chronic GT1a or GT1b HCV patients co-infected with HIV-1, and in patients who had received a liver transplant with normal hepatic function and mild fibrosis. TURQUOISE-I was conducted to evaluate the efficacy a
Slide 4: Clinical Design Summaries
abbvie VIEKIRA PAK Clinical 1 Design Summaries The clinical trial program included five randomized, global, multi-center Phase 3 trials conducted to evaluate the safety and efficacy of VIEKIRA PAK +/- RBV in different non-cirrhotic patient populations described below. In each study, RBV dose adjustm
Slide 5: Important Safety Information
abbvie VIEKIRA PAK Important Safety Information Risk of Adverse Reactions or Reduced Therapeutic Effect Due to Drug Interactions: ¢ The concomitant use of VIEKIRA PAK and certain other drugs may result in known or potentially significant drug interactions, some of which may lead to loss of therapeut
Slide 6: References
abbvie References 1 VIEKIRA PAK [package insert]. North Chicago, IL: AbbVie Inc. European Association for the Study of the Liver. Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology. 2014; vol. 60: 392-420. 3 Feld J}. Kgweley KV, Coakley E, et al. Treatment